Revenue Increased 9.2% to $258.6 million; Organic
Revenue Increased 6.4%
Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading
global medical technology company, today reported its financial
results for the first quarter ending March 31, 2017.
Highlights:
- First quarter revenue increased 9.2% over the prior year
quarter to $258.6 million, and organic revenue increased 6.4%.
Derma Sciences contributed $10.4 million of revenue to first
quarter results;
- GAAP gross margin increased 230 basis points over the prior
year quarter to 66.5%, and adjusted gross margin increased 100
basis points to 70.2%;
- Operating cash flow increased 15.4% over the prior year quarter
to $28.9 million, resulting in free cash flow conversion of 85.1%
on a trailing twelve month basis, compared to 65.4% in the prior
year period;
- Closed Derma Sciences acquisition and on track to complete
commercial integration by mid-year;
- Secured financing for the planned acquisition of Codman
Neurosurgery; and,
- Maintaining previously issued 2017 full-year sales, organic
growth, EPS and cash flow guidance.
Total revenues for the first quarter were $258.6 million,
reflecting an increase of $21.9 million, or 9.2%, over the first
quarter of 2016. Both global segments contributed to the growth,
with revenue in Orthopedics and Tissue Technologies and Specialty
Surgical Solutions increasing by 19.6% and 3.4%, respectively,
compared to the prior year.
Excluding the revenue contribution from acquisitions and the
effect of currency exchange rates and discontinued products,
revenues increased 6.4% over the first quarter of 2016.
"We are off to a solid start in 2017, which gives us increased
confidence in delivering on our full-year 2017 financial guidance,"
said Peter Arduini, Integra's president and chief executive
officer. "We completed the acquisition of Derma Sciences, launched
several new products that will drive growth in the second half of
the year, and remain on track to complete the planned acquisition
of Codman Neurosurgery in the fourth quarter of 2017."
The company reported GAAP net income of $6.4 million, or $0.08
per diluted share, for the first quarter of 2017, compared to a
GAAP net income of $13.4 million, or $0.18 per diluted share, for
the first quarter of 2016. The year-over-year declines largely
resulted from acquisition-related expenses associated with the
Derma Sciences and Codman Neurosurgery transactions.
The adjusted measures discussed below are computed with the
adjustments to GAAP reporting set forth in the attached
reconciliation.
Adjusted net income for the first quarter of 2017 was $30.9
million, an increase of 9.3% over the prior year, and compares to
adjusted net income of $28.3 million in the first quarter of 2016.
Adjusted earnings per share for the first quarter of 2017 was
$0.39, compared to $0.38, in the first quarter of 2016.
Adjusted EBITDA for the first quarter of 2017 was $55.2 million,
or 21.3% of revenue, compared to $52.1 million, or 22.0% of
revenue, in the first quarter of 2016. The slight decrease in
adjusted EBITDA margin primarily resulted from the dilution caused
by the Derma Sciences acquisition.
Operating cash flow for the first quarter was $28.9 million, an
increase of 15.4% from the prior-year period. Trailing
twelve-month adjusted free cash flow conversion ended
March 31, 2017 was 85.1%, versus 65.4% in the prior year.
Outlook for 2017
Based on first quarter results and the outlook for the remainder
of the year, the company is maintaining its full-year 2017 revenue
guidance range of $1.12 billion to $1.14 billion, and full-year
2017 organic revenue growth range of 7.0% to 8.5%. The company also
is maintaining its full-year GAAP and adjusted earnings per share
guidance ranges of $0.49 to $0.55 and $1.88 to $1.94,
respectively.
"Based on our first quarter results and the sequential
improvements that we expect over the course of the year, we remain
confident that we will achieve our full-year projections," said
Glenn Coleman, Integra's chief financial officer. "We also
successfully executed and secured an extension of our term loan
facility with favorable terms, which we will use to pay for the
planned acquisition of Codman Neurosurgery later this year."
In the future, the company may record, or
expects to record, certain additional revenues, gains, expenses, or
charges as described in the Discussion of Adjusted Financial
Measures below which will be excluded from the calculation of
adjusted EBITDA, adjusted earnings per share for historical periods
and in adjusted earnings per share guidance.
Conference Call and Presentation Available
Online
Integra has scheduled a conference call for 8:30 AM ET today,
Wednesday, April 26, 2017, to discuss financial results for the
first quarter and forward-looking financial guidance. The
conference call will be hosted by Integra's senior management team
and will be open to all listeners. Additional forward-looking
information may be discussed in a question and answer session
following the call.
Integra's management team will reference a presentation during
the conference call. That presentation can be found on
investor.integralife.com.
Access to the live call is available by dialing (719) 457-2618
and using the passcode 3686388. The call can also be accessed via a
webcast link provided on investor.integralife.com. Access to
the replay will be available through May 1, 2017, by dialing (719)
457-0820 and using the passcode 3686388. The webcast will also be
archived on the website.
Integra LifeSciences is dedicated to limiting uncertainty for
clinicians, so they can concentrate on providing the best patient
care. Integra offers innovative solutions, including leading
plastic and regenerative technologies, in specialty surgical
solutions and orthopedics and tissue technologies. For more
information, please visit www.integralife.com.
This news release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995
that involve risks, uncertainties and reflect the Company's
judgment as of the date of this release. Forward-looking
statements include, but are not limited to, statements concerning
future financial performance, including projections for revenues,
GAAP and adjusted net income, GAAP and adjusted (loss)/earnings per
diluted share, non-GAAP adjustments such as global enterprise
resource planning ("ERP") system implementation charges,
acquisition-related charges, goodwill impairment charges, non-cash
amortization of imputed interest for convertible debt, intangible
asset amortization, and income tax expense (benefit) related to
non-GAAP adjustments. Such forward-looking statements involve risks
and uncertainties that could cause actual results to differ
materially from predicted or expected results. Such risks and
uncertainties include, but are not limited to the following: the
Company's ability to execute its operating plan effectively; the
Company's ability to manufacture and ship sufficient quantities of
its products to meet its customers' demand; the ability of
third-party suppliers to supply us with raw materials and finished
products; global macroeconomic and political conditions; the
Company's ability to manage its direct sales channels effectively;
the Company's ability to maintain relationships with customers of
acquired entities; physicians' willingness to adopt and third-party
payors' willingness to provide or maintain reimbursement for the
Company's recently launched, planned and existing products;
initiatives launched by the Company's competitors; downward pricing
pressures for customers; the Company's ability to secure regulatory
approval for products in development; the Company's ability to
remediate quality systems violations; fluctuations in hospitals
spending for capital equipment; the Company's ability to comply
with and obtain approvals for products of human origin and comply
with recently enacted regulations regarding products containing
materials derived from animal sources; difficulties in controlling
expenses, including costs to procure and manufacture our products;
the impact of changes in management or staff levels; the Company's
ability to integrate acquired businesses; the impact of goodwill
and intangible asset impairment charges if future operating results
of acquired businesses are significantly less than the results
anticipated at the time of the acquisitions, the Company's ability
to leverage its existing selling organizations and administrative
infrastructure; the Company's ability to increase product sales and
gross margins, and control non-product costs; the Company’s ability
to achieve anticipated growth rates, margins and scale and execute
its strategy generally; the amount and timing of acquisition, and
integration-related costs; the geographic distribution of where the
Company generates its taxable income; the effect of legislation
effecting healthcare reform in the United States and
internationally; fluctuations in foreign currency exchange rates;
the amount of our convertible notes and bank borrowings outstanding
and other factors influencing liquidity; and the economic,
competitive, governmental, technological, and other risk factors
and uncertainties identified under the heading “Risk Factors”
included in Item 1A of Integra's Annual Report on Form 10-K for the
year ended December 31, 2016 and information contained in
subsequent filings with the Securities and Exchange
Commission. In addition, with respect to the Codman
Neurosurgery acquisition, forward-looking statements in this
document may include without limitation any statements regarding
the planned completion of the proposed acquisition, the costs and
benefits of the proposed acquisition, including future financial
and operating results, Integra’s or the Codman Neurosurgery
business’s plans, objectives, expectations and intentions and the
expected timing of completion of the proposed
acquisition. It is important to note that Integra’s
goals and expectations are not predictions of actual
performance. Actual results may differ materially from
Integra’s current expectations depending upon a number of factors
affecting the Codman Neurosurgery business and Integra’s business
and risks and uncertainties associated with acquisition
transactions. These factors include, among other things, the
following: successful closing of the proposed acquisition; the risk
that competing offers will be made for the Codman Neurosurgery
business before the binding offer is accepted; the risk that the
binding offer may not be accepted on a timely basis or at all; the
ability to obtain required regulatory approvals for the proposed
acquisition (including the approval of antitrust authorities
necessary to complete the proposed acquisition), the timing of
obtaining such approvals and the risk that such approvals may
result in the imposition of conditions, including with respect to
divestitures, that could materially adversely affect Integra, the
Codman Neurosurgery business and the expected benefits of the
proposed acquisition; the risk that a condition to closing of the
proposed acquisition may not be satisfied on a timely basis or at
all; the failure of the proposed acquisition to close for any other
reason and the risk liability to Integra in connection therewith;
access to available financing (including financing for the
acquisition) on a timely basis and on reasonable terms; the effects
of disruption caused by the proposed acquisition making it more
difficult for Integra to execute its operating plan effectively or
to maintain relationships with employees, vendors and other
business partners; stockholder litigation in connection with the
proposed acquisition; and Integra’s ability to successfully
integrate the Codman Neurosurgery business and other acquired
businesses.
These forward-looking statements are made only as of the date
hereof, and the Company undertakes no obligation to update or
revise the forward-looking statements, whether as a result of new
information, future events, or otherwise.
Discussion of Adjusted Financial Measures
In addition to our GAAP results, we provide organic revenues,
adjusted earnings before interest, taxes, depreciation and
amortization ("EBITDA"), adjusted net income, adjusted earnings per
diluted share, adjusted diluted weighted average shares
outstanding, free cash flow and adjusted free cash flow
conversion. Organic revenues consist of total revenues
excluding the effects of currency exchange rates, acquired revenues
and product discontinuances. Adjusted EBITDA consists of GAAP
net income from continuing operations, excluding: (i) depreciation
and amortization; (ii) other income (expense); (iii) interest
income and expense; (iv) income taxes; and (v) those operating
expenses also excluded from adjusted net income. The measure
of adjusted net income consists of GAAP net income from continuing
operations, excluding: (i) global enterprise resource planning
("ERP") implementation charges; (ii) structural optimization
charges; (iii) certain employee severance charges; (iv)
acquisition-related charges; (v) convertible debt non-cash
interest; (vi) intangible asset amortization expense; (vii)
discontinued product lines charges; and (viii) income tax impact
from adjustments and other items. The measure of adjusted
diluted weighted average shares outstanding is calculated by adding
the economic benefit of the convertible note hedge transactions
relating to Integra's 2016 convertible notes. The adjusted
earnings per diluted share measure is calculated by dividing
adjusted net income attributable to diluted shares by adjusted
diluted weighted average shares outstanding. The measure of
free cash flow consists of GAAP net cash provided by continuing
operating activities from continuing operations less purchases of
property and equipment. The adjusted free cash flow
conversion measure is calculated by dividing free cash flow by
adjusted net income.
Reconciliations of GAAP revenues to adjusted revenues and GAAP
Adjusted Net Income from continuing operations to adjusted EBITDA,
and adjusted net income, and GAAP earnings per diluted share to
adjusted earnings per diluted share all for the three months ended
March 31, 2017 and 2016, and the free cash flow and free cash
flow conversion for the three months ended March 31, 2017 and
2016 and the twelve months ended March 31, 2017 and 2016,
appear in the financial tables in this release.
The Company believes that the presentation of organic revenues
and the various adjusted EBITDA, adjusted net income, adjusted
earnings per diluted share, adjusted diluted weighted average
shares outstanding, free cash flow and free cash flow conversion
measures provide important supplemental information to management
and investors regarding financial and business trends relating to
the Company's financial condition and results of operations.
For further information regarding why Integra believes that these
non-GAAP financial measures provide useful information to
investors, the specific manner in which management uses these
measures, and some of the limitations associated with the use of
these measures, please refer to the Company's Current Report on
Form 8-K regarding this earnings press release filed today with the
Securities and Exchange Commission. This Current Report on
Form 8-K is available on the SEC's website at www.sec.gov or
on our website at www.integralife.com.
INTEGRA LIFESCIENCES HOLDINGS CORPORATION |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS |
(UNAUDITED) |
|
(In
thousands, except per share amounts) |
|
|
Three Months Ended March 31, |
|
2017 |
|
2016 |
Total revenues,
net |
$ |
258,636 |
|
|
$ |
236,770 |
|
|
|
|
|
Costs and
expenses: |
|
|
|
Cost of goods sold |
86,585 |
|
|
84,773 |
|
Research and
development |
15,494 |
|
|
14,451 |
|
Selling, general and
administrative |
142,497 |
|
|
111,975 |
|
Intangible asset
amortization |
4,101 |
|
|
3,471 |
|
Total costs and
expenses |
248,677 |
|
|
214,670 |
|
|
|
|
|
Operating income |
9,959 |
|
|
22,100 |
|
|
|
|
|
Interest income |
7 |
|
|
6 |
|
Interest expense |
(5,131 |
) |
|
(6,373 |
) |
Other income (expense),
net |
(90 |
) |
|
(738 |
) |
Income from continuing
operations before taxes |
4,745 |
|
|
14,995 |
|
Income tax expense |
(1,649 |
) |
|
1,576 |
|
Net income |
$ |
6,394 |
|
|
$ |
13,419 |
|
|
|
|
|
Net income per
share: |
|
|
|
Diluted net income per
share |
$ |
0.08 |
|
|
$ |
0.18 |
|
|
|
|
|
Weighted average common
shares outstanding for diluted net income per share
|
78,394 |
|
|
76,466 |
|
Segment revenues and growth in total revenues excluding the
effects of currency exchange rates, acquisitions, and discontinued
products are as follows:
(In thousands) |
|
|
|
|
Three Months Ended March 31, |
|
|
2017 |
|
|
2016 |
|
Change |
Specialty Surgical
Solutions |
$ |
156,290 |
|
$ |
151,175 |
|
3.4 |
% |
Orthopedics and Tissue
Technologies |
|
102,346 |
|
|
85,595 |
|
19.6 |
% |
Total revenue |
$ |
258,636 |
|
$ |
236,770 |
|
9.2 |
% |
|
|
|
|
Impact of changes in
currency exchange rates |
$ |
1,365 |
|
$ |
— |
|
|
Less contribution of
revenues from acquisitions* |
|
(10,404 |
) |
|
— |
|
|
Less contribution of
revenues from discontinued products |
|
(433 |
) |
|
(2,541 |
) |
|
Total organic
revenues |
$ |
249,164 |
|
$ |
234,229 |
|
6.4 |
% |
|
|
|
|
* Acquisitions include Derma Sciences |
|
Items included in GAAP net income from continuing operations and
location where each item is recorded are as follows:
(In
thousands) |
|
Three Months Ended March 31, 2017 |
|
Item |
Total Amount |
COGS(a) |
SG&A(b) |
R&D(c) |
Amort.(d) |
OI&E(e) |
Tax(f) |
Global ERP
implementation charges |
$ |
2,427 |
|
$ |
— |
$ |
2,427 |
$ |
— |
$ |
— |
$ |
— |
$ |
— |
|
Structural optimization
charges |
|
1,586 |
|
|
898 |
|
688 |
|
— |
|
— |
|
— |
|
— |
|
Acquisition-related
charges* |
|
20,317 |
|
|
643 |
|
19,674 |
|
— |
|
— |
|
— |
|
— |
|
Certain employee
severance charges |
|
125 |
|
|
— |
|
125 |
|
— |
|
— |
|
— |
|
— |
|
Discontinued product
lines charges |
|
1,025 |
|
|
1,025 |
|
— |
|
— |
|
— |
|
— |
|
— |
|
Intangible asset
amortization expense |
|
10,966 |
|
|
6,865 |
|
— |
|
— |
|
4,101 |
|
— |
|
— |
|
Estimated income tax
impact from above adjustments and other items |
|
(11,951) |
|
|
— |
|
— |
|
— |
|
— |
|
— |
|
(11,951) |
|
Total adjustments |
$ |
24,495 |
|
$ |
9,431 |
$ |
22,914 |
$ |
— |
$ |
4,101 |
$ |
— |
$ |
(11,951) |
|
|
|
|
|
|
|
|
|
Depreciation
expense |
|
8,751 |
|
|
— |
|
— |
|
— |
|
— |
|
— |
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
a) COGS - Cost of goods sold |
|
b) SG&A - Selling, general and administrative |
|
c) R&D- Research and development |
|
d) Amort. - Intangible asset amortization |
|
e) OI&E - Interest (income) expense, net and other
(income) expense, net |
|
f) Tax - Income tax expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
*
Acquisition related charges are primarily associated with the Derma
Sciences and Codman Neurosurgery acquisitions and include banking,
legal, consulting and other expenses |
Three months ended March 31, 2016 |
|
(In
thousands) |
|
Item |
Total Amount |
COGS (a) |
SG&A (b) |
Amort. (c) |
OI&E (d) |
Tax (e) |
Global ERP
implementation charges |
$ |
3,324 |
|
$ |
— |
$ |
3,324 |
$ |
— |
$ |
— |
$ |
— |
|
Structural optimization
charges |
|
1,709 |
|
|
985 |
|
724 |
|
— |
|
— |
|
— |
|
Acquisition-related
charges |
|
6,041 |
|
|
3,652 |
|
2,389 |
|
— |
|
— |
|
— |
|
Certain employee
severance charges |
|
650 |
|
|
211 |
|
439 |
|
— |
|
— |
|
— |
|
Intangible asset
amortization expense |
|
10,536 |
|
|
7,065 |
|
— |
|
3,471 |
|
— |
|
— |
|
Convertible debt
noncash interest |
|
2,064 |
|
|
— |
|
— |
|
— |
|
2,064 |
|
— |
|
Estimated income tax
impact from above adjustments and other items |
|
(9,480) |
|
|
— |
|
— |
|
— |
|
— |
|
(9,480) |
|
Total adjustments |
$ |
14,844 |
|
$ |
11,913 |
$ |
6,876 |
$ |
3,471 |
$ |
2,064 |
$ |
(9,480) |
|
|
|
|
|
|
|
|
Depreciation
expense |
|
7,717 |
|
|
— |
|
— |
|
— |
|
— |
|
— |
|
|
a) COGS - Cost of goods sold |
b) SG&A - Selling, general and administrative |
c) Amort. - Intangible asset amortization |
d) OI&E - Interest (income) expense, net and other
(income) expense, net |
e) Tax - Income tax expense |
RECONCILIATION OF NON-GAAP ADJUSTMENTS - GAAP NET
INCOME FROM CONTINUING OPERATIONS TO ADJUSTED EBITDA |
(UNAUDITED) |
(In
thousands, except per share amounts) |
|
|
Three Months Ended March 31, |
|
2017 |
|
2016 |
GAAP net income from
continuing operations |
$ |
6,394 |
|
|
$ |
13,419 |
|
Non-GAAP
adjustments: |
|
|
|
Depreciation and
intangible asset amortization expense |
19,717 |
|
|
18,253 |
|
Other (income) expense,
net |
90 |
|
|
738 |
|
Interest expense,
net |
5,124 |
|
|
6,367 |
|
Income tax expense |
(1,649 |
) |
|
1,576 |
|
Global ERP
implementation charges |
2,427 |
|
|
3,324 |
|
Structural optimization
charges |
1,586 |
|
|
1,709 |
|
Acquisition-related
charges |
20,317 |
|
|
6,041 |
|
Certain employee
severance charges |
125 |
|
|
650 |
|
Discontinued product
lines charges |
1,025 |
|
|
— |
|
|
|
|
|
Total of
non-GAAP adjustments |
48,762 |
|
|
38,658 |
|
Adjusted EBITDA |
$ |
55,156 |
|
|
$ |
52,077 |
|
|
|
|
|
RECONCILIATION OF NON-GAAP ADJUSTMENTS - GAAP NET
INCOME FROM CONTINUING OPERATIONS TO |
MEASURES OF ADJUSTED NET INCOME AND ADJUSTED EARNINGS
PER SHARE |
(UNAUDITED) |
|
(In
thousands, except per share amounts) |
|
|
Three Months Ended March 31, |
|
2017 |
|
2016 |
|
|
|
|
|
|
|
|
GAAP net income from
continuing operations |
$ |
6,394 |
|
|
$ |
13,419 |
|
Non-GAAP
adjustments: |
|
|
|
Global ERP
implementation charges |
2,427 |
|
|
3,324 |
|
Structural optimization
charges |
1,586 |
|
|
1,709 |
|
Acquisition-related
charges |
20,317 |
|
|
6,041 |
|
Certain employee
severance charges |
125 |
|
|
650 |
|
Discontinued product
lines charges |
1,025 |
|
|
— |
|
Intangible asset
amortization expense |
10,966 |
|
|
10,536 |
|
Convertible debt
noncash interest |
— |
|
|
2,064 |
|
Estimated income tax
impact from adjustments and other items |
(11,951 |
) |
|
(9,480 |
) |
|
|
|
|
Total of
non-GAAP adjustments |
24,495 |
|
|
14,844 |
|
Adjusted net
income |
$ |
30,889 |
|
|
$ |
28,263 |
|
|
|
|
|
Adjusted diluted net
income per share |
$ |
0.39 |
|
|
$ |
0.38 |
|
|
|
|
|
|
|
Weighted average common
shares outstanding for diluted net income per share |
78,394 |
|
|
76,466 |
|
Weighted average common
shares outstanding adjustment for economic benefit of convertible
bond hedge transactions |
— |
|
|
(1,306 |
) |
|
|
|
|
|
|
Weighted average common
shares outstanding for adjusted diluted net income per share |
78,394 |
|
|
75,160 |
|
|
CONDENSED BALANCE SHEET DATA |
(UNAUDITED) |
|
(In
thousands) |
|
|
March 31, 2017 |
|
December 31, 2016 |
|
|
|
|
|
|
|
|
Cash and cash
equivalents
|
$ |
124,113 |
|
|
$ |
102,055 |
|
Accounts receivable,
net |
158,234 |
|
|
148,186 |
|
Inventories, net |
239,809 |
|
|
217,263 |
|
|
|
|
|
Bank line of
credit |
855,000 |
|
|
665,000 |
|
|
|
|
|
Stockholders'
equity |
$ |
852,491 |
|
|
$ |
839,667 |
|
CONDENSED STATEMENT OF CASH FLOWS |
(UNAUDITED) |
|
(In
thousands) |
|
|
Three Months Ended |
|
|
|
|
|
|
|
|
|
March 31, 2017 |
|
March 31, 2016 |
Net cash provided by
operating activities |
$ |
28,882 |
|
|
$ |
25,030 |
|
Net cash used in
investing activities |
(193,143 |
) |
|
(6,730 |
) |
Net cash provided by
financing activities |
185,039 |
|
|
9,952 |
|
Effect of exchange rate
changes on cash and cash equivalents |
1,280 |
|
|
702 |
|
|
|
|
|
Net increase in cash
and cash equivalents |
$ |
22,058 |
|
|
$ |
28,954 |
|
|
|
|
|
RECONCILIATION OF NON-GAAP ADJUSTMENTS - GAAP OPERATING
CASH FLOW TO |
MEASURES OF FREE CASH FLOW AND FREE CASH FLOW
CONVERSION |
(UNAUDITED) |
(In thousands) |
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, |
|
2017 |
|
2016 |
GAAP net
cash provided by continuing operating activities |
$ |
28,880 |
|
|
$ |
25,030 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchases
of property and equipment from continuing operations |
|
(9,191 |
) |
|
|
(10,895 |
) |
Free cash
flow |
|
19,689 |
|
|
|
14,135 |
|
|
|
|
|
|
|
Adjusted
net income * |
$ |
30,889 |
|
|
$ |
28,263 |
|
Adjusted
free cash flow conversion |
|
63.7 |
% |
|
|
50.0 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
Twelve Months Endied March 31, |
|
2017 |
|
2016 |
GAAP net
cash provided by continuing operating activities** |
$ |
163,040 |
|
|
$ |
112,792 |
|
|
|
|
|
|
|
Purchases
of property and equipment from continuing operations |
|
(45,624 |
) |
|
|
(38,978 |
) |
Free cash
flow |
|
117,416 |
|
|
|
73,814 |
|
|
|
|
|
|
|
Adjusted
net income * |
$ |
137,990 |
|
|
$ |
112,921 |
|
Adjusted
free cash flow conversion |
|
85.1 |
% |
|
|
65.4 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
* Adjusted net income for quarters ended March 31, 2017
and 2016 are reconciled above. Adjusted net income for
remaining quarters in the trailing twelve months calculation have
been previously reconciled and are publicly available in the
Quarterly Earnings Call Presentations and the Historical Financial
Results: Continuing Operations presentation on our website at
investor.integralife.com under Events & Presentations. |
** Operating cash flow excludes $42.8M of accreted interest
payment associated with the 2016 Convertible Notes. |
|
|
|
|
|
|
The Company calculates adjusted free cash flow conversion by
dividing its free cash flow by adjusted net income. The
Company believes this measure is useful in evaluating the
significance of the cash special charges in its adjusted earnings
measures. |
|
|
|
|
|
|
INTEGRA LIFESCIENCES HOLDINGS CORPORATION |
|
RECONCILIATION OF NON-GAAP ADJUSTMENTS - GUIDANCE |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Recorded Year to Date |
|
|
Projected Year Ended |
|
(In thousands, except
per share amounts) |
March 31, 2017 |
|
|
December 31, 2017 |
|
|
|
|
|
Low |
|
|
High |
|
GAAP net income |
$ |
6,394 |
|
|
$ |
39,250 |
|
|
$ |
43,750 |
|
Non-GAAP
adjustments: |
|
|
|
|
|
|
|
|
Global ERP
implementation charges |
|
2,427 |
|
|
|
7,400 |
|
|
|
7,400 |
|
Structural optimization
charges |
|
1,586 |
|
|
|
19,000 |
|
|
|
19,000 |
|
Acquisition-related
charges |
|
20,317 |
|
|
|
78,500 |
|
|
|
78,500 |
|
Certain employee
severance charges |
|
125 |
|
|
|
125 |
|
|
|
125 |
|
Discontinued product
lines charges |
|
1,025 |
|
|
|
1,025 |
|
|
|
1,025 |
|
Intangible asset
amortization expense |
|
10,966 |
|
|
|
47,800 |
|
|
|
47,800 |
|
Estimated income tax
impact from adjustments and other items |
|
(11,951 |
) |
|
|
(44,000 |
) |
|
|
(44,000 |
) |
|
|
|
|
|
|
|
|
|
Total of non-GAAP
adjustments |
|
24,495 |
|
|
|
109,850 |
|
|
|
109,850 |
|
Adjusted net
income |
$ |
30,889 |
|
|
$ |
149,100 |
|
|
$ |
153,600 |
|
|
|
|
|
|
|
|
|
|
GAAP diluted net income
per share |
$ |
0.08 |
|
|
$ |
0.49 |
|
|
$ |
0.55 |
|
Non-GAAP adjustments
detailed above (per share) |
$ |
0.31 |
|
|
$ |
1.39 |
|
|
$ |
1.39 |
|
Adjusted diluted net
income per share |
$ |
0.39 |
|
|
$ |
1.88 |
|
|
$ |
1.94 |
|
|
|
|
|
|
|
|
|
|
Weighted average common
shares outstanding for diluted net income per share |
|
78,394 |
|
|
|
79,500 |
|
|
|
79,000 |
|
|
|
|
|
|
|
|
|
|
GUIDANCE - SPECIAL CHARGES |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Item |
YTD Amount |
|
|
FY Guidance |
|
|
COGS |
|
SG&A |
|
R&D |
|
Amort. |
|
Interest (Inc)Exp |
|
|
Tax |
|
Global ERP
implementation charges |
$ |
2,427 |
|
|
$ |
7,400 |
|
$ |
— |
|
$ |
7,400 |
|
$ |
— |
|
$ |
— |
|
$ |
— |
|
$ |
— |
|
Structural optimization
charges |
|
1,586 |
|
|
|
19,000 |
|
|
10,500 |
|
|
8,500 |
|
|
— |
|
|
— |
|
|
|
|
|
|
|
Acquisition-related
charges |
|
20,317 |
|
|
|
78,500 |
|
|
9,000 |
|
|
69,500 |
|
|
|
|
|
— |
|
|
— |
|
|
— |
|
Certain employee
severance charges |
|
125 |
|
|
|
125 |
|
|
— |
|
|
125 |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
Discontinued product
lines charges |
|
1,025 |
|
|
|
1,025 |
|
|
1,025 |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
Intangible asset
amortization expense |
|
10,966 |
|
|
|
47,800 |
|
|
31,000 |
|
|
— |
|
|
— |
|
|
16,800 |
|
|
— |
|
|
— |
|
Convertible debt
non-cash interest |
|
— |
|
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
Estimated income tax
impact from adjustments and other items |
|
(11,951 |
) |
|
|
(44,000 |
) |
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
(44,000 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
24,495 |
|
|
|
109,850 |
|
|
51,525 |
|
|
85,525 |
|
|
— |
|
|
16,800 |
|
|
— |
|
|
(44,000 |
) |
Contact:
Investor Relations:
Angela Steinway
(609) 936-2268
angela.steinway@integralife.com
Michael Beaulieu
(609) 750-2827
michael.beaulieu@integralife.com
Media:
Laurene Isip
(609) 750-7984
laurene.isip@integralife.com
Integra LifeSciences (NASDAQ:IART)
Historical Stock Chart
From Mar 2024 to Apr 2024
Integra LifeSciences (NASDAQ:IART)
Historical Stock Chart
From Apr 2023 to Apr 2024